Table 4.

Comparison of PIK3CA mutation studies in male and female breast cancer

	Male Breast Cancer		Female Breast Cancer
	Current Study	Benvenuti S et al. [20]	Benvenuti S et al. [20]	Buttitta F et al. [14]	Campbell IG et al. [3]	Saal H et al. [16]
Study population	High risk - familial	Population based	Population based	Population based	Population based	Population based
Frequency	6/57 (10.5%)	7/39 (17.9%)	14/86 (16.3%)	46/180 (25.6%)	28/70 (40.0%)	77/292 (26.4%)
Mutation Locus	3 exon 9, 3 exon 20	7 exon 20	6 exon 9, 8 exon 20	23 exon 9, 23 exon 20	15 exon 9, 9 exon 20, 3 exon 7, 1 exon 6	31 exon 9, 49 exon 20, 7 exon 7, 7 others
Clinicopathological association	Inverse correlation with BRCA2 mutation carrier status	No clinicopathological association	No clinicopathological association	Mutation seen more frequently in lobular carcinoma (46%, P < 0.001). Exon 9 more frequently seen in lobular carcinoma (30% of cases, P < 0.001).	No clinicopathological association	Association with ER positivity (P = 0.0001), PgR Positivity (0.0063) and lymph node positivity (P = 0.0375).

P-values < 0.05 in bold text